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Increased mean platelet volume in type 2 diabetes mellitus
Tip 2 diyabetes mellitusda artmış ortalama trombosit hacmi
Ezgi Coşkun Yenigün1, Gülay Ulusal Okyay1, Atakan Pirpir1, Ahmet Hondur2, İ.Safa Yıldırım1
ÖZET
Amaç: Diyabetik hastalarda vasküler komplikasyonların 
gelişiminde trombositler önemli rol oynamaktadır. Büyük 
trombositler küçüklere oranla daha aktif olup, ortalama 
trombosit hacmi (MPV) trombosit aktivitesini göstermede 
kullanılan bir belirteçdir. Biz bu çalışmamızda MPV’nin tip 
2 diyabetes mellituslu hastalarda ve diyabetin mikrovas-
küler ve makrovasküler komplikasyonlardaki ilişkisi araş-
tırmayı amaçladık.
Yöntemler: Çalışmaya Dışkapı Eğitim ve Araştırma Has-
tanesi Dahiliye polikliniğinde takipli olan 48 tip 2 diyabetli 
ve 30 sağlıklı hasta dahil edilmiştir. Tüm hastalarda tam 
kan sayımı, açlık kan şekeri ve lipid parametreleri çalı-
şıldı. Diyabetik hastalarda diyabet süresi, HbA1c düze-
yi, mikrovasküler ve makrovasküler komplikasyon varlığı 
araştırıldı. Ortalama trombosit hacmi diyabetik ve sağlıklı 
kontrol grubu arasında ve diyabetik kolda komplikasyon 
olan olmayan grup arasında karşılaştırıldı. 
Bulgular: Diyabetik hastalarda MPV, non-diyabetik sağ-
lıklılarla karşılaştırıldığında anlamlı yüksek saptandı. En 
az bir mikrovasküler komplikasyonu olan hastalarda ol-
mayanlara göre MPV belirgin yüksek saptandı. Makro-
vasküler komplikasyonu olan hastalarda MPV olmayan 
hastalara göre yüksek bulundu.
Sonuç: Hem diyabetiklerde hem de mikro-makrovasküler 
komplikasyonları olan diyabetik hastalarda MPV yüksek 
bulunmuştur. 
Anahtar kelimeler: Diyabetes mellitus; diyabetik kompli-
kasyon; ortalama trombosit hacmi
ABSTRACT
Objective: Platelet functions have important roles in the 
development  of  vascular  complications  in  diabetic  pa-
tients. Platelets with increased volume have increased 
activity compared to smaller ones; therefore, mean plate-
let volume (MPV) is used as a marker for platelet activity. 
In the present study, we evaluated MPV in patients with 
type II diabetes mellitus (DM) and its associations with 
diabetic microvascular and macrovascular complications.
Methods:  Consecutive  type  II  diabetic  patients  were 
screened from outpatient clinic of Internal Medicine De-
partment of Diskapı Yıldırım Beyazıt Education and Re-
searsch Hospital, Ankara, Turkey. A total of 48 patients 
with type II DM and 30 age and gender matched healthy 
subjects constituted the study population. For all subjects 
a complete blood count including MPV, fasting blood glu-
cose level and lipid parameters were studied. In diabetic 
patients, duration of diabetes and HbA1C level, presence 
of microvascular and macrovascular complications were 
noted  additively.  Mean  platelet  volume  was  compared 
between  diabetic  patients  and  healthy  counterparents. 
Then, among diabetic patients, MPV was compared be-
tween the ones with and without microvascular and mac-
rovascular complications. 
Results: Mean platelet volume was found significantly 
higher  in  diabetic  patients  compared  to  non-diabetic 
healthy subjects. Diabetic patients with at least one of 
the microvascular complications had significantly higher 
MPV  than  those  without  microvascular  damage.Higher 
MPV levels have also been shown in diabetics with mac-
rovascular complications compared to the ones without 
macrovascular disease.
Conclusion: Mean platelet volume was found to be high-
er in type II diabetics and those having any of microvas-
cular or macrovascular diabetic complications. 
Key words:  Diabetes  mellitus,  diabetic  complications, 
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INTRODUCTION
Diabetes mellitus (DM) impairs glucose tolerance. 
As such it is a genetically and clinically heteroge-
neous disease requiring continuous follow up. Pa-
tients with DM and vascular complications face an 
increased risk of mortality. Many studies are being 
conducted on the pathogenetic factors that play a 
role  in  complication  development  in  DM.  It  is 
thought that platelets have an effective role in the 
development of vascular complications. It has been 
shown that diabetic patients have increased throm-
botic adhesion and aggregation, thromboxane syn-
thesis and platelet factor 4 plasma levels [1,2]. 
Platelets express procoagulant proteins such as 
P-selectin and glycoprotein IIIa on their surfaces 
[3]. Large platelets that contain denser granules are 
metabolically and enzymatically more active than 
smaller  ones  and  have  higher  thrombotic  poten-
tial; hence, increased MPV might be linked with 
increased thrombotic potential [4]. Several studies 
focusing on MPV and DM have suggested a relation 
between the presence of vascular complications and 
MPV.
The aim of the present study was to evaluate 
MPV in patients with type II DM in comparison 
with a healthy control group, the determination of 
the association between MPV and vascular compli-
cations, the estimation of the correlation between 
MPV and HbA1c, fasting blood glucose and dura-
tion of diabetes.
METHODS
Patients
Consecutive forty-eight patients (59.35 ± 9.04 years 
of age, 15 male and 33 female) with the diagnosis of 
type II DM were enrolled from outpatient clinic of 
Internal Medicine Department of Dıskapı Yıldırım 
Beyazıt Education and Researsch Hospital, Ankara, 
Turkey during 4 months period. In the same time 
frame, 30 age and gender matched healthy subjects 
(13 male and 17 female) were recruited as the con-
trol group. Subjects with anemia (Hb <11g/dl for 
females and Hb <12 g/dl for males) and thrombocy-
topenia (platelet count <150.000/μL) were excluded 
from the study. 
Hypertension  was  defined  as  current  use  of 
anti-hypertensive drugs or systolic blood pressure 
> 140 mmHg, diastolic blood pressure > 90 mmHg. 
Weight  and  height  measurements  of  the  patients 
were performed without heavy outer garments and 
shoes. Body mass index was calculated with the 
weight (kg)/length²(m) formula. 
Coronary  artery  disease  was  defined  as  the 
presence of angiographically proven coronary ar-
tery  stenosis,  history  of  myocardial  infarction  or 
coronary artery bypass grafting operation and pres-
ence of current ischemic changes indicated by elec-
trocardiography. Presence of cladicatio was used as 
a sign of peripheral arterial disease and lower limb 
doppler ultrasonography was performed for these 
patients. Presence of coronary artery disease and/or 
peripheral arterial disease were accepted as macro-
vascular complications.
Retinopathy, nephropathy and neuropathy were 
assessed  as  microvascular  complications  of  DM. 
Fundoscopic examinations were performed for all 
diabetic patients. At least two microaneurysms and/
or retinal hemorrhage and/or other signs of retinal 
damage  were  recognised  as  diabetic  retinopathy. 
Twenty  four  hour  urinary  albumin  excretion  rate 
(after exclusion of infection with urine culture) was 
classified as normoalbuminuria (<30 mg/day), mi-
croalbuminuria  (30-300  mg/day)  and  macroalbu-
minuria (≥300 mg/day) according to the criteria of 
ADA (5). Patients with micro- and macroalbumin-
uria were accepted as having diabetic nephropathy. 
Symmetrical sensorineural neuropathy on neurolog-
ical examination that was also confirmed on electro-
myogram was accepted as diabetic neuropathy. The 
control group was constituted from subjects without 
laboratory abnormalities and known chronic-meta-
bolic diseases. 
The  study  was  approved  by  the  institutional 
ethics committee and all contributors gave their in-
formed consent. 
Laboratory examinations
Complete blood count, fasting blood glucose level, 
lipid parameters and HbA1c of the subjects were 
studied after 12 hours of fasting. Venous samples 
were taken into EDTA containing laboratory tubes 
for complete blood count including MPV and mea-
surements were performed within two hours after 
sample collection. The blood glucose level was de-
termined by the glucose oxidase method and HbA1c E. Ç. Yenigün et al. MPV in type 2 diabetes mellitus 19
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was measured using high-performance liquid chro-
matography.
Statistical Analysis
Data were analyzed using the Statistical Package for 
Social Sciences (SPSS) software version 11.5 for 
Windows (SPSS Inc., Chicago, IL). For continuous 
variables, the suitability of parametric test condi-
tions was checked with Kolmogorov Smirnov test. 
Student’s t test was used for parametric data and 
Mann-Whitney U test was used for non-parametric 
data. The Chi-square and Fisher’s Exact tests were 
used to establish the differences between categori-
cal variables of the study population and the control 
group. Parametric data were presented as mean ± 
standard deviations (SD) and non-parametric data 
were presented as median and interquartile range 
(IQR; the range of values lying between the 25th and 
75th centiles). Categorical variables were shown as 
frequency and percentages. The Pearson correlation 
test was used for the correlations of MPV with BMI, 
fasting blood glucose level and HbA1C. A p value 
<0.05 was considered statistically significant.
RESULTS
The baseline characteristics of the patients and con-
trol group were given in table-1. Duration of DM 
was 8.33 ± 5.4 years. Twelve of the diabetics (25 %) 
had macrovascular complications, 26 patients (54.2 
%) had HT, 15 patients (31.3 %) had retinopathy, 16 
patients (33.3 %) had nephropathy and 39 patients 
(81.2 %) had neuropathy. Mean HbA1c was 8.73 
± 2.03 %. Mean platelet volume was significantly 
higher in patients with type II DM than the healthy 
controls (9.25 ± 1.49 and 8.47 ± 0.49, respectively) 
(p<0.01)  (table-1).  Platelet  count  was  somewhat 
lower in the diabetic group; however, this differ-
ence was not significant (249.729 ± 73.479 /μL and 
279.466 ± 73.294 /μL, respectively) (p= 0.10).
Table 1 . Baseline characteristics and laboratory results of type II DM patients and healthy control group.
Diabetic Patients
(n=48)
Control Group
(n=30) P value
Age (years) 59.35 ± 9.04 57.80 ± 9.14 0.34
Gender (female/male) 33/15 17/13 0.13
BMI (kg/m²) 29.67 ± 3.39 27.32 ± 4.06 <0.01
Duration of DM (years) 6 (5-10) - -
CAD (n, %) 12 (25 %) - -
Hypertension (n, %) 26 (54.2 %) - -
Nephropathy (n, %) 16 (33.3 %) - -
Retinopathy (n, %) 15 (31.3 %) - -
Neuropathy (n, %) 39 (81.2 %) - -
HbA1c (%) 8.73 ± 2.03 - -
Fasting blood glucose (mg/dl) 184.50 (133.8 - 223) 85 (78.5 - 94) <0.01
Total cholesterol (mg/dl) 194.88 ± 46.70 181.03 ± 45.57 0.20
LDL-cholesterol (mg/dl) 110.96 ± 40.80 105.26 ± 37.62 0.54
HDL-cholesterol (mg/dl) 44.71 ± 12.50 46.76 ± 14.10 0.51
Triglyceride (mg/dl) 163 (106 - 231.8) 131 (105.8 - 157.8) 0.05
Hemoglobin (g/dl) 13.82 ± 1.12 13.84 ± 1.12 0.97
Hematocrit (%) 40.73 ± 3.37 41.68 ± 3.44 0.24
White blood cell count (/μL)  7313 ± 1883 7045 ± 1747 0.53
Platelet count (/μL)  249500 (219500 - 293750) 281000 (226250 - 338250) 0.10
MPV (fl)  9.2 ± 1.49 8.5 ± 0.49 <0.01
Abbreviations; BMI: Body mass index, DM: Diabetes mellitus, CAD: Coronary artery disease, HbA1C: Glycosylated 
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The  diabetic  patients  were  divided  into  sub-
groups depending on the presence of microvascular 
complications. Patients with at least one of the mi-
crovascular complications had slightly higher MPV 
compared to the ones without any of the complica-
tions (9.38 ± 1.47 fl and 7.85 ± 0.88 fl, respectively) 
(p= 0.048). When the groups were analysed indi-
vidually as patients with and without retinopathy 
(9.48 ± 1.60 and 9.15 ± 1.45, p= 0.48), nephropathy 
(9.25 ± 1.45 and 9.25 ± 1.53, p= 0.99) and neuropa-
thy (9.43 ± 1.47 and 8.49 ± 1.39, p= 0.09), there 
were no significance between the groups regarding 
MPV (Figure 1). The diabetic patients were classi-
fied into subgroups depending on the presence of 
macrovascular complications. Twelve patients with 
macrovascular complications showed higher MPV 
compared to the ones without macrovascular com-
plications (10.23 ± 1.66 fl and 8.93 ± 1.29 fl, respec-
tively) (p<0.01).
Figure 1. MPV levels between groups 
In type II diabetic patients there was no asso-
ciation between MPV and age (p= 0.62, r: 0.07), 
duration of diabetes (p= 0.75, r: -0.05), total cho-
lesterol level (p= 0.23, r: -0.18), LDL-cholesterol 
level (p= 0.34, r: -0.14), HDL-cholesterol level (p= 
0.22, r: -0.18), triglyceride level (p= 0.96, r: -0.01), 
HbA1C (p= 0.18, r: 0.20) and fasting blood glucose 
level (p= 0.37, r: 0.13). Mean platelet volume was 
found as similar between smoking (n= 12) and non-
smoking II diabetic patients (n= 36) (9.68 ± 1.72 
and 9.11 ± 1.40, respectively) (p= 0.26). Diabetic 
males have similar MPV values with females (9.43 
± 1.90 and 9.2 ± 1.30, respectively) (p= 0.62). 
DISCUSSION
Diabetes mellitus is a chronic disease that causes in-
creased morbidity and mortality due to its vascular 
complications. There is a need to develop risk factor 
modification to reduce the impact of complications. 
Diabetic patients are at risk of increased thrombosis 
and atherogenesis. Changes in hemostatic balance 
constitute a pathogenetic factor with a role in com-
plication development in DM. Owing to the role of 
blood platelets in hemostatic balance, changes in 
platelets in diabetic patients have been studied ex-
tensively and an increase in thrombotic adhesion, 
aggregation and secretion has been shown in many 
of these [6-8].
Mean platelet volume is an indicator showing 
thrombosis  function  and  activation.  Large  plate-
lets have metabolically and enzymatically denser 
granules than smaller ones, and display high throm-
botic  potential  [9,10].  Mean  platelet  volume  has 
been studied in many vascular diseases. Platelets 
play a pivotal role in atherothrombosis, the major 
cause  of  most  unstable  coronary  syndromes  and 
increased MPV levels have been shown as an in-
dicator  in  myocardial  infarcts  [4,11-13],  conges-
tive  heart  disease  [13],  cerebrovascular  diseases 
[14], obesity [15] and hypertensive patients [16,17]. 
There is a previous study that suggested a relation-
ship between high MPV levels and an increase in 
the frequency of restenosis in patients who received 
coronary angioplasty [18]. Another study has also 
shown a relationship between increased MPV and 
increased CAD incidence in chronic hemodialysis 
patients [19]. Increased MPV in diabetes has been 
reported in some human and animal studies, though 
not in all [20]. As in previous studies [7,20-23], we 
showed  diabetic  patients  had  significantly  larger 
MPV than non-diabetic controls. These studies have 
shown increased platelet aggregation in DM, and 
this may have a role in its vascular complications. 
Including any patient with at least one of nephropa-
thy, retinopathy or neuropathy complication in the 
‘microvascular  complication  group’,  we  found  a 
meaningful  difference  between  the  MPV  levels 
of this group and the ones with no microvascular 
complications. However, when all patients with and 
without complications were assessed separately for 
each  complication,  a  statistically  meaningful  dif-E. Ç. Yenigün et al. MPV in type 2 diabetes mellitus 21
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ference was not found between mean MPV values. 
This finding was similar to the results of previous 
studies by Keskin et al. and Hekimsoy et al. [2,21]. 
It is still debated whether platelett activation plays 
a primary pathogenetic role in the development of 
diabetic vascular complications or whether the in-
creased activity is secondary to vascular complica-
tions. Based on our findings, we are of the opinion 
that higher MPV cannot be attributed solely to the 
existence of diabetes and platelets play a primary 
role in complication development. 
In our study we found no association between 
MPV  and  HbA1c,  fasting  blood  glucose,  patient 
age, HT, hyperlipidemia and duration of diabetes. 
These findings were in agreement with the previous 
reports [21,24]. They suggested vascular damage to 
be due to more reactive platelets and claimed the 
rate of damage to be constant for the duration of the 
disease and independent of diabetic control.
Additionally, we found an association between 
higher MPV and macrovascular complications. This 
association has, to our knowledge, not been report-
ed previously.
Increases in platelet volume are often associ-
ated with decreases in platelet count [18,25], per-
haps as a result of small platelets being consumed 
in order to maintain a constant platelet functional 
mass [26]. Although the relationships is not com-
pletely understood. Association of increased plate-
let volume and reduced platelet survival in diabetic 
patients has been reported by Jones et al [27]. We 
found the number of platelets were smaller in dia-
betic patients similar to the results of Tschöpe et al 
[28], this difference was not statistically meaning-
ful. Our examination of the diabetic group showed 
a negative linear relationship between MPV and the 
number of platelets (p=0.006). 
An important point in MPV measurement is the 
ability of platelets to change their volume follow-
ing blood collection. The anticoagulant used and the 
time between sample collection and the study affect 
MPV measurement. The platelets in blood samples 
collected in EDTA tubes swell after a while. Even 
though volume change with sodium citrate is much 
less than EDTA, this agent is not appropriate for 
the counters used in practice. If samples collected 
in EDTA tubes can be studied within 2 hours, the 
results are acceptable [26]. In light of the literature, 
we have performed and recommend the analysis of 
samples collected in EDTA tubes within 2 hours.
In  conclusion,  MPV  is  a  marker  of  platelet 
function and activity. Diabetes is a complex disease 
which affects many vascular systems, and increased 
platelet volume is likely to be associated with the 
pathological processes and increased risk of vascu-
lar disease.
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